top of page
  • Glenn Hearson

Benralizumab study ANDHI shows early clinical benefits in #severe asthma patient-reported outcomes

Updated: Feb 21, 2023

Between 2017 and 2019, Liz Dark and our asthma team, led by Professor Tim Harrison of the NIHR Nottingham BRC, recruited severe asthma patients into the phase 3b #ANDHI study treating patients with #Benralizumab.


ANDHI was done to assess the efficacy of #benralizumab, including onset of effect and impact on health-related quality of life (HRQOL), exacerbation rate, lung function, and nasal polyposis symptoms.


The latest results have recently been published in the #Lancet, "Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial"; https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30414-8/fulltext


Interpretation

the results extend the efficacy profile of #benralizumab for patients with severe eosinophilic asthma, showing early clinical benefits in patient-reported outcomes, HRQOL, lung function, and nasal polyposis symptoms.




Comments


bottom of page